Direct tumor visual feedback during free breathing in 0.35T MRgRT by Kim, Taeho et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2020 
Direct tumor visual feedback during free breathing in 0.35T 
MRgRT 
Taeho Kim 
Benjamin C Lewis 
Alex Price 
Thomas Mazur 
H Michael Gach 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Taeho Kim, Benjamin C Lewis, Alex Price, Thomas Mazur, H Michael Gach, Justin C Park, Bin Cai, Erin 
Wittland, Lauren Henke, Hyun Kim, Sasa Mutic, and Olga Green 
T E C HN I C A L NO T E
Direct tumor visual feedback during free breathing in 0.35T
MRgRT
Taeho Kim1 | Benjamin C. Lewis1 | Alex Price1 | Thomas Mazur1 |
H. Michael Gach1,2 | Justin C. Park1 | Bin Cai1 | Erin Wittland1 | Lauren Henke1 |
Hyun Kim1 | Sasa Mutic1 | Olga Green1
1Department of Radiation Oncology,
Washington University School of Medicine,
St Louis, MO, 63110, USA
2Department of Radiology and Biomedical
Engineering, Washington University in St.
Louis, St Louis, MO, 63110, USA




To present a tumor motion control system during free breathing using direct tumor
visual feedback to patients in 0.35 T magnetic resonance‐guided radiotherapy
(MRgRT). We present direct tumor visualization to patients by projecting real‐time
cine MR images on an MR‐compatible display system inside a 0.35 T MRgRT bore.
The direct tumor visualization included anatomical images with a target contour and
an auto‐segmented gating contour. In addition, a beam‐status sign was added for
patient guidance. The feasibility was investigated with a six‐patient clinical evalua-
tion of the system in terms of tumor motion range and beam‐on time. Seven
patients without visual guidance were used for comparison. Positions of the tumor
and the auto‐segmented gating contour from the cine MR images were used in
probability analysis to evaluate tumor motion control. In addition, beam‐on time was
recorded to assess the efficacy of the visual feedback system. The direct tumor
visualization system was developed and implemented in our clinic. The target con-
tour extended 3 mm outside of the gating contour for 33.6 ± 24.9% of the time
without visual guidance, and 37.2 ± 26.4% of the time with visual guidance. The
average maximum motion outside of the gating contour was 14.4 ± 11.1 mm with-
out and 13.0 ± 7.9 mm with visual guidance. Beam‐on time as a percentage was
43.9 ± 15.3% without visual guidance, and 48.0 ± 21.2% with visual guidance, but
was not significantly different (P = 0.34). We demonstrated the clinical feasibility
and potential benefits of presenting direct tumor visual feedback to patients in
MRgRT. The visual feedback allows patients to visualize and attempt to minimize
tumor motion in free breathing. The proposed system and associated clinical work-
flow can be easily adapted for any type of MRgRT.
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1 | INTRODUCTION
In previous studies, tumors in the thorax were shown to move up
to 5 cm1 and rotate up to 45°2 during respiration. Conventional
respiratory motion‐compensation techniques such as surrogate‐
based respiratory gating, breath‐hold, and marker‐based tumor
tracking3–5 are clinically useful for tumor motion management but
significant variations in cycle‐to‐cycle breathing can cause treat-
ment inaccuracies.6,7 Recently, several respiratory monitoring sys-
tems3,7–10 were introduced for respiratory motion management in
radiotherapy providing respiratory guidance during radiotherapy in
addition to medical imaging.11,12 For instance, audio‐visual biofeed-
back7 uses a noninvasive external marker to measure abdominal
motion and uses audio‐visual (AV) tools to return that information
to the patient for respiratory motion guidance. Audio‐visual
biofeedback can reduce average cycle‐to‐cycle variations in breath-
ing displacement and period by up to 50% and 70%, respec-
tively.7,13 However, the applications of this system may be limited
by an insufficient correlation between tumor and surrogate
motion.6,14
Real‐time 2D tumor tracking in MR‐guided radiotherapy (MRgRT)
became clinically available in 2014.15,16 MRgRT improves local con-
trol and spares critical organs by providing superior soft tissue con-
trast resolution and real‐time imaging‐based delivery. However,
irregular tumor motion still hinders treatment efficiency in gated
radiotherapy. Visual guidance systems in MRgRT have been intro-
duced for improving tumor motion control in voluntary breath‐
hold.17,18 For example, Kim et al. displayed the treatment delivery
system (TDS) operator screen inside the bore of the treatment sys-
tem by using a video signal splitter and an MR‐compatible beam pro-
jector. In a similar approach, de Koste et al. displayed the TDS on an
MR‐compatible monitor by using a video signal splitter and an adjus-
table mirror. The splitters supply the video signal of the TDS com-
puter to an in‐room display device. There are two challenges
associated with the splitter‐based approach: (a) the TDS display
depends on video signal of a splitter; (b) displaying the entire TDS
screen to patients includes unnecessary information that may con-
fuse the patient, thus requiring further processing for advanced
visual guidance.18
In our study, we developed a visual guidance system which does
not impact the TDS display. In addition, a customizable visual guid-
ance display was added without intensive programming that opti-
mizes the information provided to the patient for efficient guidance.
Through the study, we implemented the visual guidance system in a
clinical workflow and investigated its impact on tumor motion con-
trol during free breathing in 0.35 T MRgRT.
2 | MATERIALS AND METHODS
2.A | 0.35T MR‐guided radiotherapy
A 0.35 T MRgRT MRIdian system (ViewRay Inc., Oakwood Village,
Ohio) with a linear accelerator radiation therapy delivery system
was used in this study. In our institutional clinical workflow, volu-
metric MRIs are acquired using steady‐state precession (TrueFISP)
in an axial orientation to position patients and localize treatment
targets.16 After the clinical team had reviewed the MRIs, and veri-
fied the target contours and expected dose, 2D TrueFISP cine
MRIs were acquired at 4 frames per second in a sagittal plane
during MRgRT. The acquired spatial resolution was
0.35 × 0.35 cm2 with 5, 7, or 10 mm slice thicknesses, depending
on the tracking efficiency. The tracking efficiency is related to the
shape, contrast, and image texture of targets. Cine MRIs were dis-
played on the TDS monitor in real time during radiation delivery,
as shown in Fig. 1(d). The TDS display included cine MRIs and
beam delivery information. The system paused the cine MRI dis-




F I G . 1 . Direct tumor visualization system
in 0.35 T MRgRT. (a) In‐room display
system with magnetic resonance (MR)‐
compatible projector and adjustable stand,
(b) Image display inside the bore of the
0.35 T MRgRT treatment system. (c)
Diagram of the video signal capturing,
processing, and presentation system. (d)
Example of the treatment delivery system
display including cine magnetic resonance
imaging and beam delivery information.
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2.B | Direct tumor visualization system in 0.35T
MRgRT
The direct tumor visualization system in the 0.35 T MRgRT environ-
ment is shown in Fig. 1. The direct tumor visualization system has
three components, including: (a) video signal capture from the TDS
system; (b) video signal processing for visual guidance; and (c) in‐
room display.
First, we set up dual screen output on the TDS system with
vendor's support such that the TDS display at the treatment con-
sole is independent from our signal capturing device. An Epiphan
DVI2USB 3.0 screen grabber (Epiphan video, CA) was used in
place of a video splitter to meet the high resolution
(1900 × 1200) display requirements of the TDS for physician
image viewing. The device was configured with the same resolu-
tion display extended display identification data (EDID) before
connecting to the TDS system. Figure 1(c) shows how the frame
grabber was connected between the TDS system and the visual
guidance computer.
Second, Streamlabs open broadcast software (OBS), (Logitech
International) was installed on the visual guidance computer to
provide video signal capturing, processing, and presenting for
visual guidance. Video signal processing using the software
allowed personalization of the patient’s display. For example, we
presented only 2D cine MRIs to the patient unlike previous stud-
ies that displayed the entire TDS display.17,18 In addition, visual
guidance‐specific notifications were added, such as a real‐time
beam‐status indicator on the displayed images [Fig. 1(b)]. The pro-
cessed video signal was sent to the in‐room projector through an
optic fiber.
A Hyperion MRI digital projection system (Psychology Software
Tools, Inc, PA) was used to convert and present the signal in the
treatment room as shown in Fig. 1(a). As Kim et al. suggested, we
displayed the images inside the bore of the treatment system. Addi-
tionally, an adjustable stand was developed and used to adjust the
display location for patients and a projector keystone correction was
used to minimize image distortion due to oblique projection as
shown in Fig. 1(a).
2.C | Clinical workflow of direct tumor visualization
Visual biofeedback based on direct tumor visualization was applied in
our adaptive radiotherapy workflow.15,19 The adaptive treatment plan-
ning and delivery workflows have been discussed in previous
reports.15,16 The additional workflow specific to providing direct
tumor visualization to the patient is described below. Figure 2 pre-
sents an outline of the clinical workflow of the direct tumor visualiza-
tion system, including: (a) introduction to patients; (b) patient setup; (c)
black screen for waiting; and (d) visual guidance during treatment.
First, before the patient enters the vault, they received a short intro-
duction using a prepared demonstration set of cine MRIs displayed in
the console area before the treatment started at the first fraction. The
brief introduction included an overview of the MRIs, and descriptions
of the target and auto‐segmented contours, and the beam‐status indi-
cator displayed on the visual guidance. Orientative information about
MRI images and abdominal anatomy was provided to patients since
they may not have previously viewed human MRIs. Second, we pro-
jected the demonstration cine MRIs inside the bore of the treatment
system while the patient was set up for treatment. The display location
was adjusted using an adjustable stand based on patient position
inside the bore. The size and focus of the image were adjusted based
on the patient’s preferences. Patient‐specific adjustments were
required due to differences in patient eyesight, immobilization position
and location in the bore. Third, we projected a black screen during the
treatment setup 3D MRI and the adaptive radiotherapy preparation
process. Displaying the black screen reduced patient discomfort
caused by the bright display and hid extraneous information from the
patient that might confuse them or induce stress during the MRI and
procedure preparation. Fourth, once beam delivery was ready to
begin, we provided the visual guidance display to patients. As shown
in Fig. 2, the visual guidance displayed only 2D cine MRIs with the tar-
get and auto‐segmented contours, and the beam‐status indicator. The
size and position of the displayed information, including the beam‐sta-
tus sign, were adjusted in real time while the patient was on the treat-
ment table, if needed. Patients treated without visual guidance
received the standard instructions to remain still and breathe normally
throughout the treatment process and were given periodic reminders.
F I G . 2 . Clinical workflow of the direct
tumor visualization. (a) Workflow diagram
and corresponding example displays, and
(b) Corresponding scene options on the
live streaming software, Streamlabs open
broadcast software.
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2.D | Evaluation of tumor motion control and
delivery time
Cine MRIs acquired during each treatment fraction were analyzed to
evaluate tumor motion control with and without visual guidance.
After treatment, the TDS produced a three channel RGB video file
of the cine acquisition including gating contour and tumor tracking
contours overlaid on the patient anatomy. In‐house software was
developed in MATLAB 2019b (MathWorks) to isolate the contours
from the underlying grayscale image. Once tracking contours were
extracted from each serial MRI, they were combined to produce a
probability distribution of tumor position. Tumor motion beyond the
gating contour boundary in the inferior direction was quantified
using superior‐inferior profiles. Only inferior motion was taken into
consideration because the gating target placement within the bound-
ary was at the full exhalation position, thus limiting superior excur-
sion outside of the gating target. A significant‐difference analysis
was performed using an unpaired t‐test. Tumor motion was evalu-
ated for seven patients without visual guidance, for a total of 40 full
or partial fractions (143 713 cine frames), and six patients with visual
guidance, a total of 33 full or partial fractions (142 282 cine frames),
including one patient treated both with and without visual guidance.
This patient was treated with both methods due to changes in medi-
cal condition over the course of their treatment. Patients treated
without visual guidance included two males and five females (age 55
to 71, average: 62.5), and patients treated with visual guidance
included three males and three females (age 53 to 71, average:
61.7). The treatment locations without visual guidance include four
pancreas, two liver, and one iliac. The treatment locations with visual
guidance include three pancreas, one liver, one iliac, and one lymph
node. The extent of motion and probability distribution were calcu-
lated. The treatment duty cycle was calculated as the percentage of
frames which had the target contour entirely contained by the gating
contour. Beam‐on time was recorded as a percentage, by the treat-
ment machine, from when the beam‐on button was engaged to the
end of radiation delivery, and included time required for gantry
motion and when the beam was turned off for target gating (Beam‐
on‐time/Treatment delivery time × 100). Duty cycle was calculated
separately from beam‐on time by excluding time when the gantry
was in motion.
3 | RESULTS
3.A | Implementation of direct tumor visualization
The direct tumor visualization system was successfully implemented
on a 0.35 T MRgRT system in our clinic. Implementation included
the system installation, training and instruction material preparation,
workflow development, and staff training. System adjustment and
optimization, updates to materials, and refresher training were con-
ducted in a developing loop. Patient introduction to the system and
projector adjustment required approximately seven minutes to per-
form prior to treatment, including five minutes for education at the
first fraction and two minutes for projector adjustment at each frac-
tion.
3.B | Evaluation of tumor motion control and
Beam‐on time
For the patients without visual guidance, the mean (±SD) of maxi-
mum tumor motion extent was 14.4 ± 11.2 mm (range, 2.2–
48.2 mm). Patients with the visual guidance system in place had a
mean (± SD) maximum tumor motion extent of 13.0 ± 7.9 mm
(range, 3.3–27.8 mm). There was no significant difference in maxi-
mum tumor motion extent between the two groups (P = 0.54).
When the target tracking contour was outside the gating contour,
patients without visual guidance had an excursion of >1.9 mm for
50% of the imaging time and 2.0 mm for 50% of the imaging time
with visual guidance in place. The target contour extended 3 mm
outside of the gating contour (mean ± SD) for 33.6 ± 24.9% of the
time without visual guidance, and 37.2 ± 26.4% of the time with
visual guidance (P = 0.56). The patient treated both with and without
visual guidance showed a maximum tumor motion extent of 5.2 and
4.1 mm without and with visual guidance in place, and the tracking
contour was outside of the gating contour 53% of the imaging time
both with and without visual guidance. The average distribution of
motion extent for patients with and without visual guidance is
shown in Fig. 3. The distribution of the auto‐segmented target track-
ing contour is shown in Fig. 4. The outlier motion, defined as occur-
ring less than 25% of the cine MRI images, is shown in Fig. 5. The
target tracking contour was completely inside the gating contour
74.5% ± 22.5% and 79.6% ± 25.5% of the time for patients without
and with visual guidance, respectively, when imaging was being per-
formed. There was no significant difference in the percentage of
frames the target tracking contour was completely inside the gating
contour (P = 0.63). Beam‐on time as a percentage had a mean (±SD)
of 43.9 ± 15.3% without visual guidance, and 48.0 ± 21.2% with
visual guidance. There was no significant difference in beam‐on time
as a percentage between the two groups (P = 0.34). The mean (±SD)
time from patient entry to exit of the treatment room was recorded
by the radiation therapist and was 64.5 ± 22.7 min without visual
guidance and 79.4 ± 14.8 min with visual guidance.
4 | DISCUSSION
Direct tumor visualization for patient biofeedback in 0.35 T MRgRT
was developed and implemented in our clinic. Compared to previous
studies in MRgRT, the proposed system had multiple unique features
including: (a) video signal capturing, (b) visual guidance projection,
and (c) visual display layout.
In this study, we used a frame grabber instead of a video signal
splitter. Since the TDS system requires a high display resolution, the
TDS control room display resolution must not be compromised by
any secondary display device. A secondary monitor or a projector
might reduce the TDS display resolution, but the configured frame
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grabber does not. In addition, when a video signal splitter is powered
off, neither output display receives a video signal because the video
signal splitter produces both signals. In contrast, by using a frame
grabber the TDS display remains independent and its operation is
unaffected by screen grabber status.17,18 This is important in pre-
venting treatment delays due to potential splitter malfunction or
troubleshooting.
Video signal capturing by the frame grabber provided more
options in signal processing than using a video signal splitter. Once
the video signal is received by the visual guidance computer, addi-
tional software can modify the acquired frames for generating cus-
tomizable displays that can be altered in real time to patient or
physician needs. For example, we used a live streaming freeware,
Streamlabs OBS, to crop the original video signal to only display the
cine MRI instead of the entire TDS screen, as shown in Fig. 1. We
also added the beam‐status sign to assist patients in staying focused
on motion control. Since the size and position of the main guidance
display including the beam‐status sign can be adjusted in real‐time,
patient‐specific adjustment can be applied. Additional display fea-
tures for visual guidance and remote plan review, via live streaming,
can be added using proper software, such as Streamlabs OBS.
Although not specifically assessed by this study, showing only perti-
nent treatment aspects to the patient, instead of all the information
including gantry angles and monitor units, may be important in
reducing patient anxiety from excessive information.
A similar MRI‐compatible display was used in our study com-
pared to previous studies.18 Since we displayed the images inside
the bore of the treatment system using a projector like Kim et al.,
the resulting images were distorted due to the oblique projection, so
a keystone function of the projector was used to correct image dis-
tortion. This approach is sufficient to remove the projection screen
and adjustable mirror required for a conventional setup. In our
approach, we developed an adjustable stand which can be used to
adjust the projection angle and display location for patients
F I G . 3 . The percentage of cine magnetic
resonance imaging (MRI) frames that the
target tracking contour extends outside of
the gating contour by the indicated
distance shown as patient averages. The
average of all patients is shown as a black
line. (a) without visual guidance (nVG), and
(b) with visual guidance (VG). (c) presents
an average of all patients both without and
with visual guidance (VG). (d) and (e)
shows the target tracking contour motion
outside of the gating contour for all
individual fractions of a single patient
without and with visual guidance,
respectively. Both patients in (d) and (e)
were treated for pancreatic disease.
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compared to the approach of Kim et al. This system also does not
require any additional hardware to be placed on the patient, elimi-
nating the possibility of broken components or additional cleaning
precautions.
Through this study, we investigated the implementation of the
visual guidance system in a clinical workflow. The workflow
included a brief introduction to the visual guidance system for
patients. A demonstration video for the introduction and the
patient setup was prepared. The demonstration video was espe-
cially helpful for educating patients who were unfamiliar with MRI,
anatomical images, and the visual guidance process. We included
a black screen option for use during waiting periods to prevent
displaying unnecessary information to the patient, including 3D
MR imaging and adaptive radiotherapy preparation procedures. In
addition, it reduced patient discomfort from the bright background
display of the projector. However, the black screen period
between the setup and the visual guidance was long enough for
patients to fall asleep so we informed the patients when the
visual guidance started. Since cine MRIs were displayed on the
TDS monitor once the treatment started, we ran the visual guid-
ance session as the beam‐on button was pressed. It is noted that
because the cine MRI displayed on the TDS system during gantry
F I G . 4 . Distribution of auto‐segmented target contour from cine magnetic resonance imaging (MRI) without visual guidance (a), and with
visual guidance (b) for a single fraction of six patients for each group. Individual patients are indicated by nVG(#) for no visual guidance and
VG(#) with visual guidance in place. The color bar scale indicates the percent of frames that the region was encompassed by the auto‐
segmented target contour.
F I G . 5 . Distribution outliers from auto‐segmented target contour from cine magnetic resonance images (MRI) without visual guidance (a),
and with visual guidance in place (b) for a single fraction of six patients for each group. Individual patients are indicated by nVG(#) for no
visual guidance and VG(#) with visual guidance in place. The color bar scale indicates the percent of frames that the region was encompassed
by the auto‐segmented target contour.
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motion is not updated, the visual guidance appeared frozen to the
patient.
Target tracking assessment of patients with and without the
visual guidance system in place showed that the duty cycle remained
similar. However, the target tracking contour was more likely to
extend a greater distance outside of the gating contour without
visual guidance. The target tracking contour had a greater range of
motion outside the gating contour and was more likely to be outside
of the target window, indicating that providing visual guidance has
the potential benefit of reducing motion range. However, an addi-
tional study with randomized patient cohorts would be required to
determine the true benefit. During treatment, patients were
observed to be more conscious of their breathing and attempting to
keep the displayed target contour within the gating contour, espe-
cially when the beam‐on indicator was active. Patients were not
instructed to alter their breathing during the training session but
changed their breathing pattern when presented with the beam‐on
indicator. The addition of training time to familiarize patients with
the system may reduce any total time benefit of the system, how-
ever time spent outside of the MRI bore is more desirable than
treatment time in the bore where the patient may experience dis-
comfort due to treatment positioning. It is noted that this study did
not consider number of treatment beams, beam segments, monitor
units, or setup difficulty, which could all have a significant impact on
the total time spent in the treatment room by the patient. In the
future, we will conduct additional studies to assess the time impact
in further detail.
5 | CONCLUSION
We demonstrated the clinical feasibility of direct tumor visualization
to patients in MRgRT. It allows tumor motion control in free breath-
ing, with the potential to reduce on‐table treatment time and tumor
motion range. Clinical workflow for the proposed system can be
easily adapted for any type of MRgRT.
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